2nd International Adalat® Symposium

1. Clinical Pharmacology

   1. Hemodynamic Studies on the New Coronary Therapeutic Drug Nifedipine (BAY a 1040)

      • P. F. Angelino, P. Tortore, R. Algranati

      Pages 128-139

   2. Effect of Nifedipine (Adalat) on Myocardial Oxygen Extraction and Lactate Metabolism and ST-T Segment Changes in Patients with Coronary Insufficiency during Artificial Stimulation of the Heart

      • J. Schaefer, H.-J. Schwarzkopf, M. Schoettler, R. Wilms

      Pages 140-144

   3. Hemodynamic Effect of Nifedipine (Adalat) in Patients Catheterized for Coronary Artery Disease

      • M. Van Den Brand, W. J. Remme, G. T. Meester, I. Tiggelaar-De Widt, R. De Ruiter, P. G. Hugenholtz

      Pages 145-153

2. Clinical Pharmacological Efficacy

   1. Front Matter

      Pages 155-155

      PDF

   2. Comparison of the Effects of Adalat with Other Substances on Myocardial Ischemia under Loading Conditions

      • H.-J. Becker, M. Kaltenbach, G. Kober

      Pages 156-163

   3. Left Ventricular Hemodynamics in Patients at Rest before and after Nifedipine (Adalat)

      • G. Kober, H.-J. Becker, M. Kaltenbach

      Pages 164-168

   4. Adalat and Beta Blockers; the Mechanism Studied with Two Series of Work Tests in Two Groups of Patients with Angina Pectoris

      • L.-G. Ekelund, J.-H. Atterhög

      Pages 169-173

   5. Adalat (Nifedipine) under Loading Conditions

      • G. McIlwraith

      Pages 174-177

   6. Results of a Comparative Study with Adalat: Phonomechano-Cardiograms in Normal Persons and Patients with Coronary Heart Disease

      • R. J. Esper, R. A. Machado, R. A. Nordaby, H. J. Bidoggia

      Pages 178-203

   7. Myocardial Circulation under Adalat in Different Phases of Coronary Diseases

      • H. Heeger, P. Kahn, E. Aldor

      Pages 204-210

3. Clinical Aspects: Hemodynamics, Onset and Duration

   1. Front Matter

      Pages 211-211

      PDF

   2. Coronary and Left Ventricular Dynamics under Nifedipine in Comparison to Nitrates, Beta-Blocking Agents and Dipyridamole

      • P. Lichtlen

      Pages 212-224

   3. Effect of Adalat (Nifedipine) on Left Ventricular Hemodynamics in Angina Pectoris (Comparative Study with Propranolol)

      • A. Kurita, M. Kanazawa, H. Hamamoto, G. Mabuchi

      Pages 225-233

   4. The Effect of Adalat on Coronary Circulation after Sublingual Administration

      • J. A. Köhler

      Pages 234-235

   5. Loading Tolerance after Adalat and Duration of Effect in Postmyocardial Infarction Studied in a Double-Blind Trial

      • G. Stein

      Pages 236-242

   6. The Cardiopulmonary Loading Capacity in Healthy Persons and Patients with Coronary Heart Disease after Application of Adalat

      • W. Hollmann, R. Rost, H. Liesen, O. Emirkanian

      Pages 243-247

   7. Remarks on Changes of ST Segment Depression during the Day

      • U. Henkels, G. Blümchen

      Pages 248-250

   8. Hemodynamic Study of Nifedipine Using Doppler Flowmetry

      • B. Angelsen, A. O. Brubakk, R. Rokseth

      Pages 251-257

4. Clinical Aspects: Special Studies

   1. Front Matter

      Pages 259-259

      PDF

   2. Clinical-Therapeutic and Hemodynamic Studies with Adalat, a New Coronary Active Substance

      • K. Kodama, N. Ohgitani, T. Minamino

      Pages 260-266

The First Adalat Symposium held in Tokyo in 1973, presented important experimental and clinical results which had been collected in Europe and Japan with the new coronary therapeutic agent. The European scientists had an opportunity to discuss the problems and results personally with their Japanese colleagues. The Second Adalat Symposium was held in Amsterdam within a year with the purpose of bringing together mainly scientists within Europe. The results discussed in Tokyo have been extended and supplemented through additional experiences. Contributions in basic science are presented, but most important are those clinical studies, which support and extend proof of the drug's efficacy in humans. The editors wish to express their appreciation to all those responsible for contributing to this report and, in particular, to Dr. M. SPENGLER, Dr. F. EBNER and Dr. K. BRANDAU for their editorial help, and to Dr. W. BOTTGER for the preparation of the Subject Index. We hope that this publication will be a valuable contribution toward conveying information to physicians and scientists. DiisseldorfjWuppertal, Autumn 1975 W. LOCHNER' W BRAASCH' G. KRONEBERG Contents Introduction: W. LOCHNER Present Basis of Coronary Therapy: W. LOCHNER. With 11 Figures 2 Session I. Chemistry and Experimental Pharmacology (Chairmen: A. FLECKENSTEIN and K. LANDMARK) Pharmacology of Nifedipine: G. KRONEBERG. With 8 Figures 12 Discussion Remarks 19 The Chemistry of Nifedipine: F. BOSSERT. With 9 Figures 20 Pharmacokinetics of Adalat in Animal Experiments: K. PATZSCHKE, B.

• Adalat
• angina pectoris
• chemistry
• circulation
• coronary artery disease
• diseases
• heart
• hemodynamics
• therapy

• Physiolog. Institut der Universität, Düsseldorf, Fed. Rep. Germany

  Wilhelm Lochner

• Bayer AG, Pharma Research Development, Fed. Rep. Germany

  Günther Kroneberg

Policies and ethics